Holen Sie sich die Stockscreener-App
8.8792
0.90%
-0.0808
Schlusskurs vom Vortag:
$8.96
Offen:
$9.02
24-Stunden-Volumen:
12,483
Relative Volume:
0.03
Marktkapitalisierung:
$453.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-2.8099
EPS:
-3.16
Netto-Cashflow:
$-97.15M
1W Leistung:
-9.40%
1M Leistung:
-27.93%
6M Leistung:
-23.52%
1J Leistung:
+14.87%
1-Tages-Spanne:
$8.84
$9.02
1-Wochen-Bereich:
$8.75
$9.96
52-Wochen-Spanne:
$7.39
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| KALV | 8.875 | 453.33M | 0 | -108.30M | -97.15M | -3.16 |
| VRTX | 446.63 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.99 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.33 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals CMO sells shares worth $74,765 - Investing.com India
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 Shares - MarketBeat
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 - Investing.com
Kalvista Pharmaceuticals CMO sells shares worth $74,765 By Investing.com - Investing.com UK
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by First Turn Management LLC - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Insight into TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of KalVista Pharmaceuticals Inc Shares - GuruFocus.com
Suvretta Capital Management, LLC Increases Stake in KalVista Pha - GuruFocus.com
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuti - GuruFocus.com
Capital World Investors Expands Stake in KalVista Pharmaceuticals - GuruFocus.com
Objective long/short (KALV) Report - Stock Traders Daily
KalVista Pharma (KALV) to Present at Stifel and Jefferies Healthcare Conferences | KALV Stock News - StockTitan
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Leerink Partnrs Has Bullish Estimate for KALV Q3 Earnings - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance
KalVista prices $55M stock offering - MSN
Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com
KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com
U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpHere's Why - MarketBeat
KalVista sets pricing for $60 million stock offering - Investing.com
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart
Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Yahoo Finance
KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com
Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
(KALV) Long Term Investment Analysis - Stock Traders Daily
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa
sebetralstat shows promise in phase 3 HAE trial - Investing.com India
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian
Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR
(KALV) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat
Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR
(KALV) Technical Data - Stock Traders Daily
Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat
Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa
Kalvista shares hold Buy rating, price target on HAE study - Investing.com
KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from HC Wainwright - MarketBeat
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):